• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

What Genetics are Associated with Multiple Sclerosis?
Discussion Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.” It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

MRI indicators of brain tissue loss: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study in relapsing-remitting multiple sclerosis (P7.255)
CONCLUSION: Over 36 Months, patients randomized to early initiation of GA40 showed less GM atrophy than those initiating GA40 after Month 12. Since deep GM structures showed no differences between groups, the benefit of early initiation of GA40 is inferred to be preservation of cortical GM volume. Study Supported by: Teva PharmaceuticalDisclosure: Dr. Zivadinov has received personal compensation for activities with Teva Neuroscience, Biogen Idec, EMD Serono, Novartis, Claret Medical Inc., and Genzyme Corporation as a speaker and/or consultant. Dr. Dwyer has received personal compensation for activities with EMD Serono and ...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Zivadinov, R., Dwyer, M., Bergsland, N., Ramasamy, D., Carl, E., Davis, M., Steinerman, J., Khan, O. Tags: MS and CNS Inflammatory Diseases: Clinical Trials Source Type: research

Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study (P7.273)
CONCLUSION: Early treatment with GA40 resulted in sustained reductions in ARR, lesion activity, and evolution of active lesions to chronic black holes over 36 months. No new safety signal was identified, and AEs were consistent with the well-established GA safety profile.Disclosure: Dr. Khan has received personal compensation for activities with Biogen Idec, Genzyme, Novartis, and Teva Neuroscience. Dr. Khan has received research funding from National Institutes of Health, National Institute of Neurological Disorders and Stroke, Nati Dr. Rieckmann has received personal compensation for activities with Bayer Pharmaceuticals...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Khan, O., Rieckmann, P., Boyko, A., Selmaj, K., Ashtamker, N., Davis, M., Kolodny, S., Zivadinov, R. Tags: MS and CNS Inflammatory Diseases: Clinical Trials Source Type: research

Preliminary results show improvement in MS symptoms
(NIH/National Institute of Neurological Disorders and Stroke) Combining the estrogen hormone estriol with Copaxone, a drug indicated for the treatment of patients with relapsing forms of multiple sclerosis, may improve symptoms in patients with the disorder, according to preliminary results from a clinical study of 158 patients with relapsing remitting multiple sclerosis. The findings were presented today by Rhonda Voskuhl, M.D., from the University of California, Los Angeles, at the American Academy of Neurology Annual Meeting in Philadelphia.
Source: EurekAlert! - Biology - April 29, 2014 Category: Biology Source Type: news

4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Magnetic Resonance Imaging (MRI) Outcomes From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.160)
CONCLUSIONS: Reduced frequency of new MRI lesions is maintained over 4 years among patients continuing therapy. Switching from placebo to delayed-release DMF, patients demonstrated MRI outcomes similar to those with delayed-release DMF in DEFINE/CONFIRM. Together with clinical efficacy and an acceptable safety profile, results support delayed-release DMF as a potential long-term treatment option for relapsing MS.Study Supported by: Biogen IdecDisclosure: Dr. Arnold has received personal compensation for activities with Acorda Therapeutics, Bayer Pharmaceuticals Corporation, Biogen Idec, Coronado Biosciences, EMD Serono, Ge...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Arnold, D., Fox, R., Gold, R., Havrdova, E., Kappos, L., Yousry, T., Zhang, R., Yang, M., Viglietta, V., Sheikh, S., Miller, D. Tags: MS and CNS Inflammatory Disease: Clinical Trials Outcomes Source Type: research

Recruitment of participants to a multiple sclerosis trial: The CombiRx experience.
CONCLUSION: Participants can be enrolled successfully in a clinical trial for RRMS, but factors affecting the time to achieve the requirements needed to start screening can be unpredictable and problematic. Prospective planning by the sponsors and investigators, use of central institutional review boards (IRBs), master trial agreements and secure remote desktop access to the trial database may expedite trial implementation and participant recruitment. A good scientific research question with flexible study design and active involvement of the clinicians are important factors driving recruitment. Clinical trials can be impl...
Source: Clinical Trials - April 7, 2014 Category: Research Authors: Bhanushali MJ, Gustafson T, Powell S, Conwit RA, Wolinsky JS, Cutter GR, Lublin FD, Cofield SS Tags: Clin Trials Source Type: research

Glatiramer acetate does not protect from acute ischemic stroke in mice
Conclusions Glatiramer acetate failed to protect from acute ischemic stroke in our hands. Further studies are needed to assess the true therapeutic potential of glatiramer acetate and related immunomodulators in brain ischemia.
Source: Experimental and Translational Stroke Medicine - February 27, 2014 Category: Neurology Source Type: research